5[5]Rieske P,Bartkowiak JK,Szadowska AM,et al. A comparative study of p 53/MDM2 genes alterations and p53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. J Exp Clin Cancer Res,1999,18(3):403～416.
6[6]Onda M,Matsuda S,Higaki S,et al. ErbB-2 expression is correlated w ith poor prognosis for patients with osteosarcoma. Cancer,1996,77(1):71～78.
7[7]Gamberi G,Benassi MS,Bohling T,et al. Prognostic relevance of C-my c gene expression in giant-cell tumor of bone. J Orthop Res,1998,16(1):1～7.
8[1]Ladanyi M,Cha C,Lewis R,et al. MDM2 gene amplification in metastati c osteosarcoma. Cancer Res,1993,53(1):16～18.
9[2]Press MF,Cordon-Cardo C,Slamon DJ. Expression of the HER-2/neu pr otooncogene in normal human adult and fetal tissues. Oncogene,1990,5(7):953～962 .
10[3]Carlos CC,Esther L,Marija D,et al. Molecular abnomalities of mdm2 a nd p53 gene in adult soft tissue sarcomas. Cancer Res,1994,54(3):794～799.
3Oka N, Soeda A, Inagaki A, et al. VEGF promotes tumorigenesis and angiogenesis of human gliobiastoma stem cells[ J]. Biochem Biophys Res Comm, 2007,360(3) :553 -559.
4Rajapakse N, Mendis E. Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells [ J ]. Bioorg Med Chem, 2007, 15 (14) :4891 -4896.
